| Issue Date | Title | Author(s) |
| 2022 | Biomarker Analysis and Updated Results From the Phase Iii Propel Trial of Abiraterone (abi) and Olaparib (ola) Vs Abi and Placebo (pbo) as First-Line (1l) Therapy for Patients (pts) With Metastatic Castration-Resistant Prostate Cancer (mcrpc) | Saad, F.; Armstrong, A. J.; Thiery-Vuillemin, A.; Oya, M.; Shore, N. D.; Procopio, G.; Arslan, C. |
| 2023 | Efficacy of Olaparib (ola) Plus Abiraterone (abi) Vs Placebo (pbo) Plus Abi in the Non-Brca Mutation (non-Brcam) Subgroup of Patients (pts) With Metastatic Castration-Resistant Prostate Cancer (mcprc) in the Propel Trial | Mehra, N.; Clarke, N. W.; Armstrong, A. J.; Oya, M.; Shore, N. D.; Procopio, G.; Guedes, J. D. C.; Arslan, Çağatay |
| 2022 | First-Line Anti-Egfr Agents (panitumumab or Cetuximab) Plus Chemotherapy in Patients With Metastatic Colorectal Cancer: Onco-Colon Turkey Study Subgroup Analysis | Isikdogan, A.; Turk, H.; Bilir, C.; Sendur, M.; Karabulut, B.; Artac, M.; Cicin, I. |
| 2021 | Real-Life Experience With Chemotherapy Plus Biologics in First-Line Treatment of Right-Sided, Ras Wild-Type, Metastatic Colon Cancer: a Multicenter Onco-Colon Turkey Study | Arslan, Çağatay ; Kefeli, U.; Yildirim, E.; Isikdogan, A.; Karadurmus, N.; Karabulut, B.; Cicin, I. |
| 2022 | Romiplostim for Chemotherapy-Induced Thrombocytopenia (cit) in Solid Tumors: Two Phase Iii, International, Randomized Controlled Trials (rct) | Al-Samkari, H.; Geredeli, C.; Arslan, C. ; Korantzis, I.; Dogu, G. G.; Nechaeva, M.; Salgado Fernandez, M. |
